Losartan and Kidney Function: How It Protects Your Kidneys

Losartan protects the kidneys primarily by blocking the hormone angiotensin II from squeezing the tiny blood vessels inside your kidneys, which lowers the pressure that damages their filtering units over time. In a landmark trial of people with type 2 diabetes and kidney disease, losartan cut the risk of end-stage renal disease by about 28% compared to placebo, and that benefit went beyond what its blood-pressure-lowering alone could explain. But the story of how losartan shields kidney tissue involves more than just easing vascular pressure, and some of its protective quirks can catch both patients and doctors off guard.

What Angiotensin II Does to Your Kidneys

Your kidneys filter blood through roughly a million tiny structures called glomeruli. Each glomerulus has an incoming blood vessel (afferent arteriole) and an outgoing one (efferent arteriole). Angiotensin II, a hormone your body produces when it senses low blood pressure or volume, constricts both of these vessels but squeezes the outgoing one harder. That raises the pressure inside the glomerular capillaries, which in the short term keeps your filtration rate up. Over months and years, though, the chronically high pressure damages the delicate filtering membrane. Protein starts leaking into your urine, scar tissue builds up, and kidney function gradually drops.

Losartan blocks the receptor that angiotensin II uses to trigger this constriction. By relaxing the efferent arteriole in particular, it reduces intraglomerular pressure without shutting down filtration entirely. Studies comparing losartan and related drugs confirm that these receptor blockers directly inhibit angiotensin II–induced constriction of renal microvessels, though they differ in binding strength.¹ The net effect is less mechanical stress on the glomerular membrane, less protein leaking through, and slower scarring.

The RENAAL Trial and What the Numbers Show

The strongest evidence for losartan’s kidney protection comes from the RENAAL trial, a large placebo-controlled study in patients with type 2 diabetes who already had measurable kidney damage. Patients who received losartan on top of conventional blood-pressure treatment had a 25% lower risk of their kidney function halving (measured by a doubling of serum creatinine) and a 28% reduction in reaching end-stage renal disease compared to placebo. The combined primary endpoint, which included kidney failure or death, was reduced by 16%.² Crucially, these benefits exceeded what the drop in blood pressure alone could account for, pointing to a direct protective effect on the kidneys themselves.

A follow-up analysis of the same trial data sorted patients by how advanced their kidney disease already was at the start. Losartan reduced end-stage renal disease risk across all severity levels, but the absolute benefit was greatest in those with the worst kidney function at baseline: among patients with the highest creatinine levels, an estimated 19 end-stage renal disease events were prevented per 100 patients treated over four years, compared to about 3 events prevented per 100 among those with the mildest disease.³ This finding matters practically: it tells you that starting losartan still helps even when kidney function has already declined substantially, though earlier use prevents more damage in absolute terms.

Reducing Protein in the Urine

Proteinuria, or protein leaking into urine, is both a marker and a driver of kidney damage. The more protein that seeps through damaged glomeruli, the more inflammation and scarring the kidney tubules downstream experience. Reducing proteinuria is one of the clearest ways losartan slows kidney disease progression.

In the RENAAL analysis, losartan cut proteinuria by roughly 15 to 24% more than placebo across all severity groups.³ Even in people who don’t yet have overt kidney disease, the effect is measurable. A trial in normotensive patients with type 2 diabetes and only mildly elevated urine albumin found that losartan at a 50 mg dose reduced albumin excretion by about 25% within five weeks, and bumping the dose to 100 mg pushed that reduction to about 34%.⁴ This happened without significant changes in blood pressure, reinforcing that losartan’s antiproteinuric action is at least partly independent of its blood-pressure effect.

The Initial Dip That Actually Signals Protection

One of the more counterintuitive things about losartan therapy is what happens to your estimated kidney function in the first few months. Many patients see a small but noticeable drop in their estimated glomerular filtration rate shortly after starting the drug. This often triggers alarm, and some doctors reflexively stop the medication. But a post hoc analysis of the RENAAL trial revealed that this initial dip is actually a hemodynamic effect, not damage, and it predicts better outcomes. Patients on losartan who experienced a greater acute drop in their filtration rate during the first three months had a slower long-term decline in kidney function afterward.⁵

The logic behind this is straightforward once you understand the mechanism. By relaxing the efferent arteriole, losartan lowers the pressure forcing fluid through the glomerulus. Measured filtration rate drops because the driving pressure dropped, not because filtering tissue was destroyed. It’s like turning down a fire hose: less water flows, but you’ve also stopped blasting the wall. The reduced pressure spares the glomerular membrane from chronic injury, so over the following years, function declines more slowly. The practical takeaway is that a modest rise in creatinine (generally up to about 30% above baseline) in the first weeks of therapy is expected and, within limits, reassuring. A dramatic or sustained rise, though, warrants investigation.

Beyond Hemodynamics: Fighting Scar Tissue

Losartan’s kidney protection extends below the level of blood flow. Chronic kidney disease of any type eventually produces fibrosis, where scar tissue replaces functional kidney cells. Angiotensin II drives this process partly through a signaling molecule called TGF-β, which pushes kidney cells to transform into scar-forming cells and to deposit collagen. Animal studies show that losartan suppresses this fibrotic pathway. In mice with obstructed kidneys, losartan reduced the dilation and collagen buildup in the tissue between kidney tubules, and it interfered with the molecular chain that TGF-β uses to trigger cell transformation.⁶ While much of this data comes from animal models rather than human biopsies, the anti-fibrotic dimension helps explain why losartan’s clinical benefits go beyond what blood pressure reduction alone can achieve.

The Uric Acid Bonus

Among all the angiotensin receptor blockers on the market, losartan has a quirk that sets it apart: it lowers uric acid. High uric acid levels are linked to gout, kidney stones, and possibly faster kidney decline. Losartan blocks a transporter in the kidneys called URAT1, which normally reabsorbs uric acid from the urine back into the blood. By inhibiting this transporter, losartan lets more uric acid leave through the urine. A study comparing losartan to candesartan in hypertensive patients found that losartan significantly reduced serum uric acid with a corresponding increase in uric acid clearance, while candesartan did not change these parameters at all.⁷

This is not a class effect shared by all similar drugs; it’s specific to losartan’s molecular structure. For patients who have both kidney disease and elevated uric acid, this can be a meaningful bonus. Whether this uric-acid-lowering effect independently contributes to losartan’s kidney protection over the long term is still debated, but it’s often a tipping factor when a doctor is choosing among drugs in this category.

Losartan in Non-Diabetic Kidney Disease

Most of the headline evidence for losartan comes from studies of diabetic nephropathy, but the drug is also used in other kidney conditions. In IgA nephropathy, an immune-mediated disease that is one of the most common causes of kidney inflammation worldwide, a trial of low-dose losartan in normotensive patients found that proteinuria dropped from a baseline average of roughly 0.8 grams per day to about 0.4 grams per day after twelve months. This reduction occurred without any meaningful change in blood pressure, and a marker of tubular injury also improved.⁸ These findings suggest that losartan’s protective mechanism applies broadly to conditions where glomerular pressure and proteinuria are driving damage, not just to diabetes.

Researchers have catalogued a range of kidney-related benefits over the roughly two decades since losartan became widely available, including slowing the progression of diabetic nephropathy, reducing proteinuria in various contexts, and controlling hypertension that often coexists with kidney disease.⁹

Sodium Intake and Why Diet Amplifies the Effect

How much salt you eat has a surprisingly large impact on how well losartan protects your kidneys. When your sodium intake is high, your body dials down its renin-angiotensin system because blood volume is already up. That might sound like a good thing, but it also means losartan has less angiotensin II activity to block, blunting the drug’s antiproteinuric effect. A randomized trial in proteinuric patients without diabetes tested a low-sodium diet, losartan, and a diuretic (hydrochlorothiazide) in different combinations. Losartan alone reduced proteinuria by about 30%. Adding a low-sodium diet to losartan pushed the reduction to roughly 55%, and adding the diuretic to losartan achieved a nearly identical 56% reduction.¹⁰

In practical terms, cutting sodium intake nearly doubled the kidney benefit of losartan in that trial. A low-sodium diet alone, without losartan, still reduced proteinuria by about 22%, underscoring that dietary sodium matters whether or not you’re on medication. For patients who struggle with strict sodium restriction, adding a diuretic can achieve a comparable enhancement. The point here is that losartan is not a free pass to eat whatever you like; it works best as part of a broader approach to managing kidney stress.

Potassium, Monitoring, and Drug Interactions

Because losartan reduces aldosterone (the hormone that normally drives potassium excretion), potassium levels can rise. In patients with healthy kidneys, this is rarely a problem. In people with impaired kidney function, the risk is real. A study of losartan in hypertensive patients with various degrees of renal impairment found that dangerous potassium elevation requiring drug discontinuation was uncommon, affecting only one patient in the study.¹¹ But uncommon does not mean negligible. Higher potassium after starting losartan can itself reflect more severe underlying kidney disease, meaning the patients most at risk for hyperkalemia are also those who may benefit most from the drug’s kidney protection.¹² Regular blood work to check potassium and creatinine is standard practice whenever you’re on losartan, especially in the first few weeks and after dose changes.

A more serious concern is the so-called “triple whammy,” a combination of an angiotensin blocker like losartan, a diuretic, and a nonsteroidal anti-inflammatory drug (NSAID) like ibuprofen or naproxen. Each of these drugs alone affects kidney blood flow in a different way; together they can starve the kidneys of blood and cause acute kidney injury. Risk factors for this complication include older age, pre-existing chronic kidney disease, dehydration, diabetes, and heart failure.¹³ Modeling studies confirm that dehydration and heightened sensitivity to these drugs are key contributors.¹⁴ The practical lesson: if you’re on losartan and a diuretic, avoid over-the-counter NSAIDs whenever possible, and stay well hydrated, especially in hot weather or during illness.

Why Losartan Must Be Avoided in Pregnancy

Losartan and all drugs that block the renin-angiotensin system are strictly contraindicated during pregnancy. The fetal kidneys rely on angiotensin II signaling to develop normal blood flow and function. Blocking this system during pregnancy disrupts fetal vascular perfusion and kidney development, and has been associated with serious harm including kidney failure in the newborn, low amniotic fluid, and skull malformations.¹⁵ Women of childbearing age who need losartan for kidney protection are typically counseled to use effective contraception and to switch to a pregnancy-safe alternative before conceiving.

Losartan Versus ACE Inhibitors for the Kidneys

Both losartan and ACE inhibitors like enalapril block the renin-angiotensin system, but they do it at different points. ACE inhibitors prevent angiotensin II from being made; losartan lets it get made but blocks its receptor. For kidney protection, the outcomes are broadly similar, and guidelines generally treat the two drug classes as interchangeable for this purpose. The main practical difference is side effects. A long-term comparison of losartan and enalapril in hypertensive patients with type 2 diabetes and early nephropathy found that enalapril caused significantly more cough and raised uric acid levels compared with losartan.¹⁶ The cough, which affects up to 10-15% of ACE inhibitor users, is driven by a buildup of bradykinin that ACE inhibitors cause but losartan does not. For patients who can’t tolerate an ACE inhibitor because of cough, losartan is usually the first alternative considered.

Genetic Variation in How the Drug Works

Losartan is a prodrug. Your liver enzyme CYP2C9 converts it into an active metabolite called EXP-3174, which is actually more potent at blocking the angiotensin receptor than losartan itself. Genetic variations in the CYP2C9 gene can change how efficiently this conversion happens. A study of kidney disease patients found that in those with secondary kidney diseases like diabetic nephropathy or hypertensive kidney damage, people carrying certain CYP2C9 variants had significantly different blood pressure responses to losartan compared to those with the normal gene version.¹⁷ In primary kidney diseases like glomerulonephritis, the genotype differences were less pronounced, though a trend toward different proteinuria responses was observed.

Pharmacogenomic testing for CYP2C9 is not yet routine before prescribing losartan, but it may explain why some patients respond robustly while others see limited benefit. If you’ve been on losartan for months and your blood pressure and proteinuria haven’t responded as expected, CYP2C9 variation is one possible explanation worth discussing with your doctor.

Combining Losartan with Newer Kidney-Protective Drugs

SGLT2 inhibitors, a class of drugs originally developed for diabetes, have emerged in recent years as powerful kidney protectors in their own right. Naturally, researchers are exploring whether combining them with losartan produces additive benefits. An experimental study in mice with Alport syndrome, a genetic form of kidney disease, found that dapagliflozin (an SGLT2 inhibitor) enhanced the kidney-protective effect of losartan. Interestingly, the same enhancement did not occur when dapagliflozin was paired with olmesartan, a stronger angiotensin blocker, suggesting that the combination’s effectiveness may depend on which specific drugs are paired.¹⁸ This is still early-stage animal research, but it reflects a broader clinical trend: many patients with chronic kidney disease today are prescribed both an angiotensin blocker and an SGLT2 inhibitor, and understanding how these drugs interact at the kidney level is an active area of investigation.